Krebs Biochemicals and Industries — 360° view

Krebs Biochemicals and Industries, a company in the Pharmaceuticals industry, reported revenue of ₹5.79 crore and a net loss of ₹5.40 crore for the September 2026 quarter.

Krebs Biochemicals and Industries (NSE: KREBSBIO) closed at ₹57.08 on 20 Nov 2026, down 15.2% over the past year. Its market capitalisation is ₹123 crore.

Share price
₹57.08 (20 Nov 2026)
Market cap
₹123 Cr (20 Nov 2026)
Revenue
₹6 Cr (September 2026 quarter)
Net profit
₹-5 Cr (September 2026 quarter)
ROCE
-15.4% (FY26)
ROE
% (FY26)
Book value
₹-79.1 (FY26)
Dividend yield
0.00% (last 12 months to 20 Nov 2026)
52-week high / low
₹76.85 / ₹38.33 (20 Nov 2026)
1-year return
-15.2% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: KREBSBIO

Incorporated in 1991, Krebs Biochemicals & Industries Ltd is presently engaged in manufacturing of active pharmaceutical ingredients.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.